Preventing Clinical Events in PAH

Elaine, a Young Patient With Advanced Symptoms

Further Examination Reveals Signs of PH

Confirming the Diagnosis

Initial Risk Assessment Determines Initial Treatment

Treatment Options in PAH

Increasing Use of Combination Therapy

AMBITION Trial: Confirmed Benefit of Upfront Combination Therapy

When to Add Prostanoid Therapy?*

Continuously Reassess and Get Patient to Goal

Elaine Improves on Dual Combination Therapy

Next Steps for Low-Risk Patient?

Importance of Thinking About the Future of Individual Patients Importance of Thinking About the Future of Individual Patients . . . NOT the Past

GRIPHON: Adding Selexipag as Third Therapy

GRIPHON: Improving Long-Term Outcomes With a More Aggressive Approach

Watch Closely and Take Action if Condition Deteriorates

Next Steps for High-Risk Patient?

Hospitalization Portends Worse Outcome

Morbidity Events in SERAPHIN and GRIPHON

SERAPHIN Month 3 Landmark: Association Between Morbidity Before Month 3 and Mortality

SERAPHIN: Association Between Morbidity and Mortality at Any Landmark Timepoint*

GRIPHON Month 3 Landmark: Association Between Morbidity Before Month 3 and Mortality

GRIPHON: Association Between Morbidity and Mortality at Any Landmark Time Point*

GRIPHON: Association Between Individual Morbidity Components and Mortality

Achieving Low-Risk Status in PAH

Registry Data Confirm Need for Early Diagnosis and Treatment Intensification

Conclusion

Abbreviations

Abbreviations (cont)